2nd Arctic Meeting on Clinical Tuberculosis, Umeå!
22nd March, University Hospital of Umeå, Lecture hall Betula and Common Ground
On behalf of the Tuberculosis Center Arctic we welcome you to attend the 2nd Arctic Meeting on Clinical Tuberculosis.!
This is a joint meeting for clinical TB researchers and staff working hands on with TB on a daily basis. There will be lectures, discussions, mingle and team-building activities. The language of the meeting is English.
The 2nd Arctic Meeting on Clinical Tuberculosis is part of the WORLD TB DAY 2019.
This year’s topics are:
- Tuberculosis in Migrants
- Pediatric Tuberculosis – A Holistic Approach to TB in the Family
- Treatment Strategies and Outcome Measures for MDR TB
Organising committee:
Johan Normark
Olena Rzhepishevska
This email address is being protected from spambots. You need JavaScript enabled to view it.
Deborah Frithiof
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Organisations supporting the meeting:
- The Tuberculosis Center Arctic
- Dep of Infectious Diseases at Norrlands University Hospital
- Dep of Pediatrics at Norrlands University Hospital
- Department of Clinical Microbiology and Molecular Infection Medicine Sweden (MIMS), Umeå University
- TBnet
Picture: Mycobacterium tuberculosis bacteria, (Scanning electron micrograph), Credit: National Institute of Allergy and Infectious Diseases, National Institutes of Health
GOLD SPONSOR:
2nd Arctic Meeting on Clinical Tuberculosis, Umeå, 22nd March 2019
08:30 Registration and coffee
09:00 Introduction and Welcome
Andreas Winroth, Head of the TB Center Arctic
Oliver Billker, Director of MIMS
SESSION 1 PEDIATRIC TUBERCULOSIS
Chair persons: Johan Normark and Maria Björmsjö
9:15 Keynote lecture: The Global Burden of Child TB: Tools to Turn the Tide
Anna Mandalakas, Professor of Pediatrice and Tropical Medicine, Baylor College of Medicine, Houston, USA
10:00 Pediatric TB Management in a High Endemic Setting of TB and HIV
Judy Orikiiriza, MD, PhD, Infectious Diseases Institute, College of Health Sciences Makerere University in Uganda
10:30 Questions to speakers, comments
10:45 Holistic Approach to TB in the Family – Case discussion seminarium
Deborah Fritiof, Department of Pediatrics, Umeå University Hospital
Therese Thunberg Department of Infectious Diseases, Umeå University Hospital
11:45 Lunch and Poster Session
SESSION 2 MDR TUBERCULOSIS – TREATMENT STRATEGIES AND OUTCOME DEFINITIONS
12:45 Management of Multidrug-Resistant Tuberculosis
Christoph Lange, Professor, Medical Director, Clinical Tuberculosis Center, German Center for Infection
Research (DZIF), Borstel Hospital and University of Lübeck, Germany; affiliated professor, Umeå University
13:30 Does One Size Really Fit All? Therapeutic Drug Monitoring During TB Treatment
Lina Davies Forsman, Karolinska University Hospital, Solna, Stockholm
14:00 Questions, comments
14:15 Coffee and Poster Session
SESSION 3 TUBERCULOSIS IN MIGRANTS
14:45 Pediatric TB in Refugees - Diagnosis and Treadtment on the Run
Folke Brinkmann, MD, PhD, University Children`s Hospital Bochum, Germany
15:15 TB Control Strategies in Adult Migrants
Kayvan Bozorgmehr, MD, Department of General Practice & Health Services Research, Heidelberg University Hospital, Germany
15:45 Questions, Comments
15:55 Best Arctic Abstract Oral Presentation and Best Arctic Poster Prize and announcement of TBnet photo contest winner
Presenting: Anders Johansson and Christoph Lange
16:25 Ending of the Meeting
Johan Normark
Department of Infectious Diseases, Umeå University Hospital, and The Laboratory for Moecular Infection Medicine Sweden (MIMS)
2nd Arctic Meeting on Clinical Tuberculosis, Umeå, 22nd March 2019
Anna Maria Mandalakas, Professor of Pediatrice and Tropical Medicine, Baylor College of Medicine, Houston, TX, US
Anna Mandalakas has extensive experience conducting large-scale community based epidemiologic studies in the US and in resource-limited countries. Over the past 20 years, she has incrementally developed a clinical research platform from which to study the diagnosis, prevention, and pathophysiology of Mycobacterium tuberculosis infection in children. In 2012, Anna joined Baylor College of Medicine and Texas Children’s Hospital to establish and direct their Global Tuberculosis Program. Collaborating with new colleagues and building upon the existing infrastructure of the Baylor Pediatric AIDS Initiative, she created a unique translational research platform that aims to promote child survival and contribute knowledge to the field of childhood TB and HIV. Her team’s translational research arena also affords an outstanding opportunity to train tomorrow’s Global Health leaders and develop capacity in the TB high-burden setting where they serve.
Publications: https://www.ncbi.nlm.nih.gov/pubmed/?term=mandalakas+A
Title of the talk: The Global Burden of Child TB: Tools to Turn the Tide
Outlines: global burden of child TB and implications of the case detection gap (WHO report and modeling literature); TB transmission cascade and importance of interventions throughout the cascade; active case finding strategies and contact tracing guidelines; TB preventive treatment (historical origins, safety data, new short course regimens, use within HIV); partnership to build sustainable capacity in high TB burden settings
Christoph Lange, Professor, Medical Director, Clinical Tuberculosis Center, German Center for Infection Research (DZIF), Borstel Hospital and University of Lübeck, Germany; affiliated professor, Umeå University
Christoph Lange studied biology at Kiel University and the University of Freiburg. He then studied medicine at the Witten/Herdecke University, where he completed his PhD in 1995. After several positions abroad, he completed his postdoctoral qualification in internal medicine and became senior physician in 2004. Since 2005, Christoph Lange has headed the “Clinical Infectology” research group at the FZB and the Clinical Tuberculosis Center at the German Center for Infection Research (DZIF). Since 2018, Christoph Lange is a Medical Director of Research Center Borstel Hospital. He is a co-founder and a Steering Board member of TBnet, a European network for clinical TB research (www.tbnet.eu). His scientific work predominantly focuses on multidrug-resistant tuberculosis (MDR-TB) epidemiology in Europe as well as the development and implementation of individualized tuberculosis treatment methods.
Source: http://www.europeanlung.org/en/news-and-events/news/professional-focus-christoph-lange
Title of the talk: Management of Multidrug-Resistant Tuberculosis
Publications: https://www.ncbi.nlm.nih.gov/pubmed/?term=Lange+Christoph+tuberculosis
Judy T Orikiiriza, MD, PhD, Infectious Diseases Institute, College of Health Sciences Makerere University in Uganda
Judy T Orikiiriza is a senior pediatrician researcher in infectious diseases especially targeting the poverty related diseases. She is a clinician scientist and a research fellow at the Infectious Diseases Institute, College of Health Sciences Makerere University in Uganda. She has special interest in improving the diagnosis and management of Pediatric Tuberculosis in resource limited settings to ensure early intervention and improved child survival utilizing household approach. Her post-doc work will be researching on TB-Malaria-HIV co-infection burden and drug-drug interactions (DDIs) among HIV infected Children in Uganda and the policy implications. In collaboration with other researchers from Umea, Republic of Ireland, USA and Uganda she is also interested in work targeting evaluation of innate and adaptive immune responses during TB infection in pediatric population of HIV+ and HIV exposed negative individuals: work in progress.
Title of the talk: Pediatric TB Management in a High Endemic Setting of TB and HIV
Outline: pediatric TB-HIV-malaria epidemiology in Uganda; Impact of HIV and malaria (?) on the pathogenesis of TB; Management of TB/HIV/malaria in children; Availability of pediatric drug formulations; DOT?; in or out patients?; treatment follow up; prognosis; MDR in HIV infected children; immune reconstitution inflammatory syndrome; ongoing research with my collaborations in Pediatric TB; conclusions and paving a better way forward
Kayvan Bozorgmehr (MD, MSc), Head of Research Group, Dept. of General Practice & Health Services Research, Heidelberg University Hospital, Germany
Kayvan Bozorgmehr is a medical doctor and social epidemiologist based at the Department of General Practice & Health Services Research at Heidelberg University. He obtained his medical doctorate from the Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medicine Berlin, and completed a postgraduate Master of Science in Public Health at Umeå University. His scientific interests are in the area of structural, social and economic determinants of health and health system organisation, with a particular focus on equity aspects, migration and transnational interdependencies. He leads national and international research projects on health and health care among forced migrants and has published extensively on this topic.
Title of the talk: TB Control Strategies in Adult Migrants
Outline: the presentation outlines strategies for the prevention and control of TB in adult migrants considering the migration trajectory from country of origin, transit to destination. Using research findings and examples of TB control in Germany and other European countries, ways forward towards more targetted and efficient strategies for TB prevention and control will be discussed.
Lina Davies Forsman, Karolinska University Hospital, Solna, Stockholm, Sweden (MD, PhD)
Lina Davies Forsman, MD, PhD, has previously worked as a Senior Medical Officer in Tugela Ferry, South Africa, with HIV and tuberculosis (TB), especially with multidrug-resistant tuberculosis (MDR-TB). She works as a Senior Consultant at Karolinska University Hospital Solna and is a member of the Swedish MDR-TB National Concilium as well as a board member of the Tuberculosis Research Centre at Karolinska Institutet. Her research concerns different strategies to improve treatment outcome of TB/MDR-TB, for instance with the aid of therapeutic drug monitoring.
Title of the talk: Does One Size Really Fit All? Therapeutic Drug Monitoring During TB Treatment
The dose of 10 mg/kg rifampicin was chosen in the 60s, mainly due to fear of toxicity and due to high costs. Low drug exposure to TB drugs has been linked to acquired drug resistance and treatment failure. Therapeutic drug monitoring can uncover low drug exposure, allowing for dose adjustments. Is therapeutic drug monitoring warranted for patients in Sweden?
Folke Brinkmann, MD, PhD, University Children`s Hospital Bochum, Department of Pulmonology, Bochum, Germany
Folke is a steering board member of TBnet (www.tbnet.eu).and pTBnet (www.tb-net.org/index.php/ptbnet)
Title of her talk: Pediatric TB in Refugees - Diagnosis and Treadtment on the Run
Outline: based on studies below
Universal screening for latent and active TB in asylum seeking children, Bochum and Hamburg, Germany, September 2015 to November 2016; Mueller-Hermelink M, Kobbe R, Methling B, Rau C, Schulze-Sturm U, Auer I, Ahrens F, Brinkmann F.; Euro Surveill; 2018 Mar;23(12).
Tuberculosis in young refugees; Ritz N, Brinkmann F, Santiago Garcia B, Tebruegge M, Kampmann B; Paediatric Tuberculosis Network European Trials group (ptbnet); Lancet. 2015 Dec 19;386(10012):2475-6.
